{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:59:00Z","timestamp":1795183140316,"version":"4.10.3"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Patients with Crohn\u2019s disease face an elevated risk of colorectal cancer, in part due to underlying chronic inflammation. Biologic therapy is the mainstay of medical treatment; however, the impact of treatment on colorectal cancer\u2013related outcomes remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To investigate the association between prior exposure to biologic treatment and colorectal cancer\u2013related outcomes in patients with underlying Crohn\u2019s disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTINGS:<\/jats:title>\n            <jats:p>High volume, tertiary colorectal surgery department.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Adults (older than 18 years) diagnosed with Crohn\u2019s disease and colorectal cancer who underwent curative operation between 1998 and 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTION(S):<\/jats:title>\n            <jats:p>Exposure to any biologic IBD medication before cancer diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>Survival and recurrence outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>A total of 56 patients were included with a median age of 52.5 years (interquartile range, 18.9 years) at the time of surgery; 19 patients (33.9%) were treated with biologics before surgery; 10 (52.6%) received infliximab, 2 (10.5%) received adalimumab, and 7 (36.8%) received multiple biologics. Rectal cancer (57% vs 43.2%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.02) and well-differentiated or moderately differentiated tumors (93% vs 50%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.005) were more common in the biologic exposure group. Exposure to biologics was associated with a higher 5-year disease-free survival rate (80% vs 45%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.048), whereas the 5-year overall survival (93% vs 57%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.19) and 5-year recurrence rates (7% vs 31%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.18) were numerically but not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>Retrospective, single-center study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>In patients with Crohn\u2019s disease and colorectal adenocarcinoma who underwent curative surgery, those previously exposed to biologic therapy were more likely to have well-differentiated or moderately differentiated tumors, which were more likely to be distal to the splenic flexure. Biologic exposure was associated with significantly higher 5-year disease-free survival. These findings suggest that treatment of inflammation in patients with Crohn\u2019s disease fundamentally alters carcinogenesis pathways. See <jats:bold>Video Abstract<\/jats:bold>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LA TERAPIA BIOL\u00d3GICA SE ASOCIA CON MEJORES RESULTADOS ONCOL\u00d3GICOS EN EL C\u00c1NCER COLORRECTAL ASOCIADO A LA ENFERMEDAD DE CROHN<\/jats:title>\n            <jats:p>\n                                 <jats:bold>ANTECEDENTES:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Los pacientes con enfermedad de Crohn enfrentan un riesgo elevado de c\u00e1ncer colorrectal, en parte debido a la inflamaci\u00f3n cr\u00f3nica subyacente. La terapia biol\u00f3gica es el pilar del tratamiento m\u00e9dico; sin embargo, el impacto del tratamiento en los resultados relacionados con el c\u00e1ncer colorrectal sigue sin estar claro.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>OBJETIVO:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Investigar la asociaci\u00f3n entre la exposici\u00f3n previa al tratamiento biol\u00f3gico y los resultados relacionados con el c\u00e1ncer colorrectal en pacientes con enfermedad de Crohn subyacente.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>DISE\u00d1O:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Estudio de cohorte retrospectivo.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>ESCENARIO:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Departamento de cirug\u00eda colorrectal de alto volumen de tercer nivel<\/jats:p>\n            <jats:p>\n                                 <jats:bold>PACIENTES:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Adultos (&gt;18 a\u00f1os) diagnosticados con enfermedad de Crohn y c\u00e1ncer colorrectal que se sometieron a una operaci\u00f3n curativa entre 1998 y 2020.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>INTERVENCI\u00d3N(ES):<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Exposici\u00f3n a cualquier medicamento biol\u00f3gico para la EII antes del diagn\u00f3stico de c\u00e1ncer.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>PRINCIPALES MEDIDAS DE RESULTADOS:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Resultados de supervivencia y recurrencia<\/jats:p>\n            <jats:p>\n                                 <jats:bold>RESULTADOS:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Se incluyeron 56 pacientes, con una mediana de edad de 52.5 a\u00f1os (RIC: 18.9 a\u00f1os) en el momento de la cirug\u00eda; 19 (33.9%) pacientes fueron tratados con agentes biol\u00f3gicos antes de la cirug\u00eda; 10 (52.6%) recibieron infliximab, 2 (10.5%) recibieron adalimumab y 7 (36.8%) hab\u00edan recibido m\u00faltiples agentes biol\u00f3gicos. El c\u00e1ncer rectal (57% frente a 43.2%, p = 0.02) y los tumores bien o moderadamente diferenciados (93% frente a 50%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.005) fueron m\u00e1s comunes en el grupo de exposici\u00f3n a agentes biol\u00f3gicos. La exposici\u00f3n a agentes biol\u00f3gicos se asoci\u00f3 con una mayor tasa de supervivencia libre de enfermedad a 5 a\u00f1os (80% frente a 45%, p = 0.048), mientras que la supervivencia general a 5 a\u00f1os (93% frente a 57%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.19) y las tasas de recurrencia a 5 a\u00f1os (7% frente a 31%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.18) fueron num\u00e9ricamente, pero no estad\u00edsticamente significativas.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>LIMITACIONES:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>Estudio retrospectivo de un solo centro.<\/jats:p>\n            <jats:p>\n                                 <jats:bold>CONCLUSIONES:<\/jats:bold>\n                              <\/jats:p>\n            <jats:p>En pacientes con enfermedad de Crohn y adenocarcinoma colorrectal que se sometieron a cirug\u00eda curativa, aquellos expuestos previamente a terapia biol\u00f3gica tuvieron m\u00e1s probabilidades de tener tumores bien\/moderadamente diferenciados, y ten\u00edan m\u00e1s probabilidades de estar distales al \u00e1ngulo espl\u00e9nico, asociados con una supervivencia libre de enfermedad a 5 a\u00f1os significativamente mayor. Estos hallazgos sugieren que el tratamiento de la inflamaci\u00f3n en pacientes con enfermedad de Crohn altera fundamentalmente las v\u00edas de la carcinog\u00e9nesis. <jats:italic toggle=\"yes\">(Traducci\u00f3n\u2014Dr. Jorge Silva Velazco<\/jats:italic>)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dcr.0000000000003550","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T23:00:17Z","timestamp":1737673217000},"page":"227-233","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Biologic Therapy Is Associated With Improved Oncologic Outcomes in Crohn\u2019s Disease\u2013Associated Colorectal Cancer"],"prefix":"10.1097","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-2425","authenticated-orcid":false,"given":"Bhuwan","family":"Giri","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Holubar","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liska","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lavryk","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Human Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Valente","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Steele","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9161-5806","authenticated-orcid":false,"given":"Leonardo C.","family":"Duraes","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"R1-20250123","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clcc.2016.02.002","article-title":"Colorectal cancer in patients with inflammatory bowel disease: the need for a real surveillance program.","volume":"15","author":"Fornaro","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"R2-20250123","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fimmu.2012.00107","article-title":"Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer.","volume":"3","author":"Rubin","year":"2012","journal-title":"Front Immunol"},{"key":"R3-20250123","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2036.2006.02854.x","article-title":"Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn\u2019s disease.","volume":"23","author":"Canavan","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-20250123","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: a meta-analysis.","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"key":"R5-20250123","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cgh.2005.12.035","article-title":"Colorectal cancer prognosis among patients with inflammatory bowel disease.","volume":"4","author":"Delaunoit","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-20250123","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.crohns.2014.02.015","article-title":"Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland.","volume":"8","author":"Jussila","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R7-20250123","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.mayocp.2015.03.024","article-title":"Effect of medications on risk of cancer in patients with inflammatory bowel diseases: a population-based cohort study from Olmsted County, Minnesota.","volume":"90","author":"Yadav","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"R8-20250123","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"R9-20250123","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study.","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R10-20250123","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.14309\/ajg.0000000000002149","article-title":"Effect of biologics on the risk of advanced-stage inflammatory bowel disease-associated intestinal cancer: a nationwide study.","volume":"118","author":"Seishima","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R11-20250123","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41389-023-00492-0","article-title":"Molecular mechanisms in colitis-associated colorectal cancer.","volume":"12","author":"Zhou","year":"2023","journal-title":"Oncogenesis"},{"key":"R12-20250123","first-page":"139","article-title":"Remicade\u00ae (infliximab): 20 years of contributions to science and medicine.","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"key":"R13-20250123","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10620-015-3940-1","article-title":"Survival of colorectal cancer in patients with or without inflammatory bowel disease: a meta-analysis.","volume":"61","author":"Ou","year":"2016","journal-title":"Dig Dis Sci"},{"key":"R14-20250123","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(19)32545-0","article-title":"Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study.","volume":"395","author":"Ol\u00e9n","year":"2020","journal-title":"Lancet"},{"key":"R15-20250123","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2012.06.016","article-title":"Effects of cancer treatment on inflammatory bowel disease remission and reactivation.","volume":"10","author":"Axelrad","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-20250123","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/ibd\/izy053","article-title":"Cancer-associated chemotherapy induces less IBD exacerbations and a reduction of IBD medication afterwards.","volume":"24","author":"Koc","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R17-20250123","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/apt.16155","article-title":"Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.","volume":"53","author":"Gordon","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20250123","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/SLA.0b013e3181e61e69","article-title":"Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn\u2019s and ulcerative colitis based on three decades of experience.","volume":"252","author":"Kiran","year":"2010","journal-title":"Ann Surg"},{"key":"R19-20250123","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.14309\/ajg.0000000000001941","article-title":"Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: an English population-based study.","volume":"117","author":"Birch","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"R20-20250123","first-page":"e416","article-title":"Biologic therapy is associated with improved oncologic outcomes in Crohn\u2019s associated colorectal cancer [ASCRS abstract SS04].","volume":"67","author":"Giri","year":"2024","journal-title":"Dis Colon Rectum"}],"container-title":["Diseases of the Colon &amp; Rectum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DCR.0000000000003550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T23:00:22Z","timestamp":1737673222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DCR.0000000000003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dcr.0000000000003550","relation":{},"ISSN":["0012-3706","1530-0358"],"issn-type":[{"value":"0012-3706","type":"print"},{"value":"1530-0358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}